WittGen Inc. provides a virtual cell-to-patient profiling technology powered by single-cell generative AI for clinical leaders and biopharmaceutical researchers. The company's platform transforms archived bulk RNA samples and pathological image data into regulator-ready patient stratification insights and cellular-level biomarkers to de-risk clinical trials and accelerate oncology drug development.
Subscribe to see WittGen Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
WittGen Inc. is a biotechnology company headquartered in Berkeley, United States. Its most recent funding round raised $180,000 in May 2023. Xcout tracks 2 named people at WittGen Inc., including Yun Rhie (Co-founder & CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $180,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of WittGen Inc.'s closest competitors — see the full list of competitors and alternatives →
Shift Bioscience is a biotechnology research company based in Cambridge, United Kingdom, that employs generative AI virtual cell models to understand gene activation and cellular reprogramming.
SwitchPoint Bio Holding, Inc. operates a platform that combines precision epigenomics and artificial intelligence to analyze cellular biology from blood samples. The company provides biomarker discovery, patient stratification, and treatment response mechanism readouts to support drug development and clinical research.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Blank Bio is an applied AI research lab headquartered in San Francisco, California, training foundation models for RNA. Founded in 2025, the company focuses on RNA intelligence for precision medicine.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Immunai, Inc. is a for-profit biotechnology company founded in 2018, headquartered in New York City with substantial operations in Israel. The company specializes in single-cell genomics and immunology to map the immune system and accelerate therapeutic discovery.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about WittGen Inc.? Suggest a correction · Work at WittGen Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.